Gelonghui March 14 | Haohai Biotech (688366.SH) disclosed an investor relations activity record table showing that the medical and aesthetic market is rapidly updating and iterating, and beauty seekers are also very enthusiastic about new brands, so some downstream institutions are considering the cost side and are beginning to generate some product customization requirements.
Currently, the largest share of the company's customized product revenue is Haiwei, the company's first-generation hyaluronic acid. The main reason is that Haiwei has been on the market for more than ten years, the quality of its products has been fully verified, and the terminal price is also very friendly.